SEP 1 6 2004

EXPRESS MAIL NO. EV207697428US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Tongtong Wang et al.

Application No.

10/007,700

Filed

November 30, 2001

For

COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF LUNG CANCER

Art Unit

1632

Docket No.

210121.455C17

Commissioner for Patents Washington, DC 20231

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references, as required under 37 C.F.R. § 1.98, are enclosed). Documents on the attached Form PTO-1449 were cited in a Partial International Search Report from corresponding foreign application PCT/US01/21065 (copy enclosed herewith), mailed October 21, 2002, and in a Written Opinion from corresponding foreign application PCT/US01/47576, mailed October 11, 2002, a copy of which is not enclosed herewith. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information

they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

I hereby certify that each of the references set forth on the attached form PTO-1449 were cited in communications from a foreign patent office in counterpart foreign applications not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Please acknowledge receipt of this Third Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Julie K. Urvater, Ph.D. Registration No. 50,461

JAU:ljt

Enclosures:

Postcard
Form PTO-1449
Form PTB/SB/21
Copies of Cited References (5)
Copy of Partial International Search Report for PCT/US01/21065
Copy of Written Opinion for PCT/US01/47576

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

EXPRESS MAIL NO. EV207697428US

Sheet 1 of 1

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY, BOCKET NO. 210121.455C17		APPLICATION NO. 10/007,700				
THIRD SU	PPL	MENTAL INFORI STATEMEN		CLOSURE	APPLICANTS Tongtong Wang et al.						
(Use several sheets if nec			cessary)		FILING DATE November 30, 2001	GROUP ART UNIT					
			U.S.	PATENT I	DOCUMENTS			-			
"EXAMINER (NITIAL			DATE	NAME		CLASS SUBCLASS		FILING DATE IF APPROPRIATE			
	AA	5,589,579	12/31/96	Torczynsk	ci et al.	536 23.1					
	ΑВ					!	<u> </u>				
	AC					į .					
	ΑD		·						- "		
FOREIGN PATENT DOCUMENTS											
		DOCUMENT NUMBER	DATE		COUNTRY				ATTON NO		
	AE	WO 99/54738	10/28/99	WIPO		:	<u>.</u>	YES	טא		
	АF	WO 00/61612	10/19/00	WIPO		:					
	AG					<u> </u>	· · · · · · · · · · · · · · · · · · ·	1			
	АН			_		!					
	AI					- 					
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)											
	LA				characterization of a r		ene expressec	l in mu	ltiple		
		cancers," On	cogene 12:7	741-751, 19	96.						
	Güre, A.O. et al., "Human Lung Cancer Antigens Recognized by Autologous							 Antibod	ies:		
		Definition of	Definition of a Novel cDNA Derived from the Tumor Suppressor," Cancer Research 58:								
		1 <u>034</u> -1041, N	March 1, 199	98.		· · · · · · · · · · · · · · · · · · ·					
	AL					<u> </u>					
	AM					:	, <u> </u>				
	AN					i					
EXAMINER DATE CONSIDERED									<u> </u>		
EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).											
		vincemance and not cons	racinac co	nda or mas roma.	wini next communication to appli	CEDI(S),					

This Page is Inserted by IIFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS
image cut off at top, bottom or sides
FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
GRIY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IIFW Image Problem Mailbox.